MaxCyte (MXCT) Scheduled to Post Quarterly Earnings on Tuesday

MaxCyte (NASDAQ:MXCT) will release its earnings data after the market closes on Tuesday, May 7th. Analysts expect MaxCyte to post earnings of ($0.14) per share for the quarter. Investors that wish to listen to the company’s conference call can do so using this link.

MaxCyte (NASDAQ:MXCT) last issued its quarterly earnings results on Tuesday, March 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.05. MaxCyte had a negative net margin of 91.85% and a negative return on equity of 15.90%. The company had revenue of $15.67 million during the quarter, compared to the consensus estimate of $15.60 million. On average, analysts expect MaxCyte to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

MaxCyte Trading Down 1.6 %

Shares of NASDAQ:MXCT opened at $3.77 on Friday. MaxCyte has a 52 week low of $2.45 and a 52 week high of $5.55. The company’s 50 day moving average is $4.13 and its two-hundred day moving average is $4.34. The company has a market cap of $394.12 million, a PE ratio of -10.19 and a beta of 1.36.

Wall Street Analyst Weigh In

MXCT has been the subject of several research analyst reports. Stephens restated an “overweight” rating and issued a $11.00 target price on shares of MaxCyte in a report on Tuesday, April 23rd. William Blair reaffirmed an “outperform” rating on shares of MaxCyte in a report on Wednesday, March 13th. Finally, BTIG Research cut their target price on MaxCyte from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, March 13th.

About MaxCyte

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.